Brought to you by 
Biosimilars start-up Epirus raises $36mm in its Series B round
30 May 2014
Executive Summary
Epirus Biopharmaceuticals Inc. (biosimilar mAbs and therapeutic proteins) raised $36mm in a Series B financing led by new investor Livzon Mabpharm (a division of public Chinese biotech Livzon Pharmaceutical Group). Additional participants included new backers Adage Capital, Greenwoods Investment, Gibralt US Inc., Monashee Capital Partners LP, and an affiliate of Mousse Partners, along with returning investors TPG Biotech, Montreux Equity Partners, and 5AM Ventures. Leerink Partners LLC was the placement agent.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Generic Drugs
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Biosimilars start-up Epirus raises $36mm in its Series B round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice